1. Scrip
  2. >>Business

After Lixi: What Zealand Is Doing Next

 
• By Sten Stovall

Zealand CEO Britt Meelby Jensen says the Danish developer of novel peptides for treating gastrointestinal and metabolic diseases is successfully raising its global profile via a growing proprietary pipeline.

Magnify
Zealand's CEO Seeks To Focus Attention On Its Proprietary Pipeline • Source: Shutterstock

Denmark-basedZealand Pharma AS says its profile among international investors has benefited hugely since its shares were listed on the US Nasdaq last August, giving it exposure to highlight a promising late-stage proprietary pipeline and ongoing collaborations with Sanofi and Boehringer Ingelheim GMBH.

Hitherto largely known for developing the Sanofi-partnered GLP-1 receptor agonist Lyxumia (lixisenatide), the Danish biotech has under its CEO Britt...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.